The newly released PDTx, now RESET and RESET-O, deliver a self-directed 12-week course of cognitive behavioral therapy that incentivizes patients to conform to treatment.
The seed funding will be used to grow the company's team and develop its technology.
The New York-based company will use the investment to grow its partnerships and coverage among payers and move into Medicare populations in 2025.
The algorithms are used to detect valvular heart disease.
The company helps FQHCs, STD and Ryan White clinics develop, operate and grow in-house pharmacy programs focused on HIV and Hepatitis C patient populations.
The AHA and MDisrupt will also co-develop a platform to enable expert referrals and disseminate evidence-based science to healthcare technology innovators.
The alliance streamlines verification of patient-driven record demands to Selfii's patient data network.
The company will be subject to a 12-month follow-up review period to assure that it does not fall below NYSE standards.
The AI-enabled technology measures musculoskeletal structures from an MRI scan.
The company will use the funds to accelerate its product expansion on a global scale.
